Xiao Dong Wang

Co-Founder at BeiGene Ltd.

Xiao Dong Wang

Xiao Dong Wang

Co-Founder at BeiGene Ltd.

Overview
Career Highlights

BeiGene Ltd.
Beigene (Beijing) Co. Ltd.
Joyant Pharmaceuticals, Inc.

RelSci Relationships

3621

Number of Boards

4

Birthday

1963

Age

56

Relationships
RelSci Relationships are individuals Xiao Dong Wang likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at BeiGene Ltd.

Relationship likelihood: Strong

Partner at Hillhouse Capital Group Ltd.

Relationship likelihood: Strong

Acting Head of Medicinal Chemistry at Beigene (Beijing) Co. Ltd.

Relationship likelihood: Strong

Head of Biologics at Beigene (Beijing) Co. Ltd.

Relationship likelihood: Strong

Head of Discovery Biology at Beigene (Beijing) Co. Ltd.

Relationship likelihood: Strong

Research Head of Chemistry at Beigene (Beijing) Co. Ltd.

Relationship likelihood: Strong

Head of Molecular Sciences at Beigene (Beijing) Co. Ltd.

Relationship likelihood: Strong

Head of International Investments at Baker Bros. Advisors LP

Relationship likelihood: Strong

Managing Director at Baker Bros. Advisors LP

Relationship likelihood: Strong

Former Investment Manager at The Goldman Sachs Group, Inc.

Relationship likelihood: Strong

Paths to Xiao Dong Wang
Potential Connections via
Relationship Science
You
Xiao Dong Wang
Co-Founder at BeiGene Ltd.
Education
Class of 1984

Beijing Normal University is a school.

UT Southwestern Medical Center is distinctive for its overall quality and for the strength of its three core missions of education, research, and patient care. These mission components are highly interdependent; each is integral to and enhances the others.UT Southwestern consists today of three degree-granting schools and a University Health System of hospitals and clinics. Its faculty is renowned for including six Nobel Laureates (one now Emeritus) and many members of the National Academy of Sciences and Institute of Medicine, and UT Southwestern Medical Center is either nationally ranked or rated as high performing in nearly a dozen specialties by U.S. News & World Report.

Memberships
Member
Current

The National Academy of Sciences (NAS) formed the Committee on International Security and Arms Control (CISAC) in 1980 as a permanent committee to bring the resources of the Academy to bear on critical problems of international security and arms control. CISAC, in the Policy and Global Affairs Division, draws from the nation’s finest scientific, technical, engineering and medical talent to advise the government, contribute to the work of non-governmental organizations, and inform the public about scientific and technical issues related to international security and arms control. CISAC’s work benefits from a rotating membership of distinguished scientists, policy and military experts. The Committee carries out its mandate through a variety of activities that receive financial support from public and private sponsors.

Career History
Assistant Professor, Department of Chemistry
Effective 09/2019

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Core Member
Effective 09/2019

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

Foreign Associate
2013 - Current

The Chinese Academy of Sciences is the linchpin of China’s drive to explore and harness high technology and the natural sciences for the benefit of China and the world. Comprising a comprehensive research and development network, a merit-based learned society and a system of higher education, CAS brings together scientists and engineers from China and around the world to address both theoretical and applied problems using world-class scientific and management approaches. Since its founding, CAS has fulfilled multiple roles — as a national team and a locomotive driving national technological innovation, a pioneer in supporting nationwide S&T development, a think tank delivering S&T advice and a community for training young S&T talent. Now, as it responds to a nationwide call to put innovation at the heart of China’s development, CAS has further defined its development strategy by emphasizing greater reliance on democratic management, openness and talent in the promotion of innovative research. With the adoption of its Innovation 2020 programme in 2011, the academy has committed to delivering breakthrough science and technology, higher caliber talent and superior scientific advice. As part of the programme, CAS has also requested that each of its institutes define its “strategic niche” — based on an overall analysis of the scientific progress and trends in their own fields both in China and abroad — in order to deploy resources more efficiently and innovate more collectively. As it builds on its proud record, CAS aims for a bright future as one of the world’s top S&T research and development organizations.

Boards & Committees
Member, Scientific Advisory Board
Current

Tennor Therapeutics Suzhou Ltd. manufactures pharmaceutical products. It specializes in research and development of new drugs for the treatment of digestive diseases caused by pathogens, including those resistant to available antibiotics. The company was founded by Zhen Kun Ma in 2013 and is headquartered in Suzhou, China.

Member, Scientific Advisory Board
Current

Beigene (Beijing) Co. Ltd., part of BeiGene Ltd., is a company headquartered in Beijing, China. The firm develops pharmaceuticals.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
N/A
2004

The National Academies of Science operates as a private non-profit organization that provides advice in sciences, engineering and medicine. It conducted through seven major program areas: Behavioral and Social Sciences and Education, Earth and Life Studies, Engineering and Physical Sciences, Health and Medicine, Policy and Global Affairs, Transportation Research Board, and the Gulf Research Program. The company was founded on March 3, 1863 and is headquartered in Washington, DC.

$1 - $999
2004

The National Academy of Sciences (NAS) formed the Committee on International Security and Arms Control (CISAC) in 1980 as a permanent committee to bring the resources of the Academy to bear on critical problems of international security and arms control. CISAC, in the Policy and Global Affairs Division, draws from the nation’s finest scientific, technical, engineering and medical talent to advise the government, contribute to the work of non-governmental organizations, and inform the public about scientific and technical issues related to international security and arms control. CISAC’s work benefits from a rotating membership of distinguished scientists, policy and military experts. The Committee carries out its mandate through a variety of activities that receive financial support from public and private sponsors.

Transactions
Details Hidden

BeiGene Ltd. issued USD American Depositary Shares

Investments
Details Hidden

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Details Hidden

Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Xiao Dong Wang. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Xiao Dong Wang's profile does not indicate a business or promotional relationship of any kind between RelSci and Xiao Dong Wang.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/xiao-dong-wang-3870766
  • https://relationshipscience.com/person/xiao-dong-wang-3870766